Minimally manipulated murine regulatory T cells purified by reversible Fab Multimers are potent suppressors for adoptive T‐cell therapy
- 15 September 2017
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 47 (12) , 2153-2162
Abstract
The transfer of regulatory T cells, either freshly isolated, or modified, represents a promising therapeutic approach to dampen misdirected immune responses, like autoimmune diseases, chronic inflammatory syndromes and graft versus host disease. Clinical isolation of highly pure regulatory T cell (Treg) populations is still challenging and labeling reagents can influence their viability and functionality, potentially altering the potency of isolated Treg cell products. Here we show that reversible Fab multimer‐based Treg purification can prevent conventional antibody label‐induced interferences in vitro and in vivo. Remaining isolation reagents negatively interfere with Treg engraftment efficacy in C57BL/6 wild‐type mice due to Fcγ‐receptor‐ as well as IL‐2 receptor‐mediated mechanisms. Using a preclinical model for acute GvHD, we further show that purified ‘label‐freed’ Tregs are protective at substantially lower cell numbers as compared to conventional nonreversible antibody staining, translating into significantly improved survival of mice treated with minimally manipulated Tregs. These findings have important clinical relevance for future Treg‐based cell therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (TP‐A10/13)
- Technische Universität München
This publication has 30 references indexed in Scilit:
- Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cellsNature Immunology, 2013
- Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell SortingPLOS ONE, 2012
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kineticsBlood, 2011
- In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII+ phagocytesEuropean Journal of Immunology, 2010
- Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applicationsClinical and Experimental Immunology, 2009
- CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cellsBlood, 2009
- Isolation of CD4+CD25+ Regulatory T Cells for Clinical TrialsTransplantation and Cellular Therapy, 2006
- CD4+CD25+ Immunoregulatory T CellsJournal of Experimental Medicine, 2002
- Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow TransplantationJournal of Experimental Medicine, 2002
- The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethalityBlood, 2002